Instant-view-PLUS immunochemical Fecal Occult Blood Test

K173212 · Alfa Scientific Designs, Inc. · KHE · Feb 15, 2018 · Hematology

Device Facts

Record IDK173212
Device NameInstant-view-PLUS immunochemical Fecal Occult Blood Test
ApplicantAlfa Scientific Designs, Inc.
Product CodeKHE · Hematology
Decision DateFeb 15, 2018
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 864.6550
Device ClassClass 2

Indications for Use

The Instant-view-plus™ Immunochemical Fecal Occult Blood Test is a qualitative immunoassay for detection of Fecal Occult Blood. It is intended for professional and over-the-counter use.

Device Story

Instant-view-plus™ Immunochemical Fecal Occult Blood Test is a chromatographic immunoassay for detecting human hemoglobin (hHb) in feces. Device consists of a test strip in a plastic cassette using Driven Flow™ technology. User collects fecal sample using an applicator; sample is mixed with detection buffer and dispensed into cassette sample well. If hHb concentration is ≥50 ng/mL, anti-hHb antibodies conjugated with colloidal gold bind to hHb, forming a burgundy test line (T-line) on a nitrocellulose membrane. A control line (C-line) confirms proper flow. Used in professional settings or at home by lay individuals. Results are visually interpreted by the user/clinician. Presence of T-line indicates potential GI bleeding, prompting further clinical investigation. Benefits include non-invasive screening for colorectal cancer and other GI disorders.

Clinical Evidence

No clinical diagnostic studies were performed. Evidence consists of analytical bench testing, including repeatability and reproducibility studies across three sites with untrained users, demonstrating high agreement. Prozone/hook effect testing showed no interference up to 500,000 ng/mL. Specificity testing confirmed no significant cross-reactivity with animal hemoglobins or common dietary/supplemental interferents. Method comparison with the predicate device (n=299) showed 97.7% overall percent agreement. Consumer study with untrained users confirmed performance consistency.

Technological Characteristics

Chromatographic immunoassay using Driven Flow™ technology. Test strip contains conjugate pad with mouse anti-hHb antibodies conjugated with colloidal gold; nitrocellulose membrane with anti-hHb (T-line) and goat anti-mouse IgG (C-line). Cassette form factor. Qualitative visual readout. No external energy source. Stable for 24 months at 8–23°C.

Indications for Use

Indicated for the qualitative detection of fecal occult blood in human stool samples. Intended for use by professionals and lay individuals (over-the-counter) as an aid in the detection of gastrointestinal bleeding associated with disorders such as diverticulitis, colitis, polyps, and colorectal cancer.

Regulatory Classification

Identification

An occult blood test is a device used to detect occult blood in urine or feces. (Occult blood is blood present in such small quantities that it can be detected only by chemical tests of suspected material, or by microscopic or spectroscopic examination.)

Special Controls

*Classification.* Class II (special controls). A control intended for use with an occult blood test is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

Predicate Devices

Reference Devices

Submission Summary (Full Text)

{0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY A. 510(k) Number: K173212 B. Purpose for Submission: Modification of a previously cleared assay C. Measurand: Human hemoglobin (hHb) in feces D. Type of Test: Chromatographic immunoassay E. Applicant: Alfa Scientific Designs, Inc. F. Proprietary and Established Names: Instant-view-plus™ Immunochemical Fecal Occult Blood Test G. Regulatory Information: 1. Regulation section: 21 CFR 864.6550, Occult blood test 2. Classification: Class II 3. Product code: KHE, Reagent, Occult Blood 4. Panel: Hematology (81) {1} 2 H. Intended Use: 1. Intended use(s): The Instant-view-plus™ Immunochemical Fecal Occult Blood Test is a qualitative immunoassay for detection of Fecal Occult Blood. It is intended for professional and over-the-counter use. 2. Indication(s) for use: Same as Intended Use 3. Special conditions for use statement(s): For prescription use and over-the-counter use 4. Special instrument requirements: Not applicable I. Device Description: The Instant-view-plus Immunochemical Fecal Occult Blood Test is a Driven Flow chromatographic immunoassay consisting of a test strip housed in a plastic cassette. J. Substantial Equivalence Information: 1. Predicate device name(s): INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test and Instant-View Fecal Occult Blood Rapid Test 2. Predicate 510(k) number(s): K070660 and K021423 3. Comparison with predicate: | Similarities | | | | | --- | --- | --- | --- | | Item | Device Instant-view-plus Immunochemical Fecal Occult Blood Test | Predicate INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test | Predicate Instant-View Fecal Occult Blood Rapid Test | {2} | Similarities | | | | | --- | --- | --- | --- | | Item | Device Instant-view-plus Immunochemical Fecal Occult Blood Test | Predicate INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test | Predicate Instant-View Fecal Occult Blood Rapid Test | | Intended use | The Instant-view-plusImmunochemical Fecal Occult Blood Test is a qualitative immunoassay for detection of Fecal Occult Blood. It is intended for professional and over- the-counter use. | The INSTANT-VIEW Fecal Occult Blood (FOB) Rapid Test is a qualitative immunoassay for the detection of Fecal Occult Blood by non- professional, lay individuals as an over- the-counter product for home use. Measurement of FOB is a useful as an aid to detect blood in stool as found in a number of gastrointestinal disorders, e.g. diverticulitis, colitis, polyps, and colorectal cancer. It is intended for over-the-counter use. The Fecal Occult Blood (FOB) Rapid Test is a qualitative immunoassay for the detection of Fecal Occult Blood by non- professional, lay individuals as an over-the-counter product for home use. Measurement of FOB is a useful as an aid to detect blood in stool as found in a number of gastrointestinal disorders, e.g. diverticulitis, colitis, polyps, and colorectal cancer. It is intended for over-the-counter use. | This Fecal Occult Blood (FOB) Rapid Test is an immunochemical device intended for the qualitative detection of Fecal Occult Blood by laboratories or physicians offices. It is useful to determining gastrointestinal (GI) bleeding found in a number of gastrointestinal (GI) disorders, e.g., diverticulitis, colitis, polyps, and colorectal cancer. This test is recommended for use in 1) routine physical examinations, when hospital patients are first admitted, 2) hospital monitoring for bleeding in patients, 3) screening for colorectal cancer or gastrointestinal bleeding from any source. | {3} | Similarities | | | | | --- | --- | --- | --- | | Item | Device Instant-view-plus Immunochemical Fecal Occult Blood Test | Predicate INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test | Predicate Instant-View Fecal Occult Blood Rapid Test | | Sample type | Human feces | Same | Same | | Assay cut-off | 50 ng/mL (human hemoglobin in human fecal sample mixed with detection buffer) | Same | Same | | Differences | | | | | --- | --- | --- | --- | | Item | Device Instant-view-plusImmunochemical Fecal Occult Blood Test, K173212 | Predicate INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test K070660 | Predicate Instant-ViewFecal Occult Blood Rapid Test K021423 | | Test principle | Chromatographic immunoassay using Driven Flow™ Technology | Lateral flow chromatographic immunoassay | Lateral flow chromatographic immunoassay | | Test device | Cassette | Cassette and dip strip | Cassette and dip strip | | Assay Reading Time | 1–10 minutes | 4–7 minutes | 5–10 minutes | # K. Standard/Guidance Document Referenced (if applicable): The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]: Guidance for Industry and Food and Drug Administration Staff. Issued on: July 28, 2017. # L. Test Principle: This assay is a Driven Flow chromatographic immunoassay. The device consists of one test strip in a plastic cassette. The test strip consists of: - A conjugate pad treated with mouse anti-human hemoglobin antibodies conjugated with colloidal gold. - A strip of nitrocellulose membrane with a Test line (T-line) and a Control line (C-line). The T-line is coated with anti-hHb antibodies, and the C-line is coated with goat anti-mouse IgG antibodies. {4} When an adequate volume of test specimen is dispensed into the sample well of the cassette, the test specimen migrates across the test strip. If the concentration of hHb in the specimen is at or above 50 ng/mL, the T-line visibly appears as a burgundy line. The intensity of the T-line may vary according to the concentration of the hHb in the sample. If the concentration of hHb in the sample is below 50 ng/mL, a T-line does not visibly appear. The C-line is coated with goat anti-mouse IgG antibody, which binds to the conjugated monoclonal antibody regardless of whether hHb is present in the sample. ## M. Performance Characteristics (if/when applicable): All manufacturer’s predetermined performance acceptance criteria were met. ### 1. Analytical performance: #### a. Precision/Reproducibility: Repeatability was evaluated in a study by two trained laboratory professionals using three Instant-view-plus Immunochemical Fecal Occult Blood Test kit lots. Hemoglobin free fecal samples were collected and spiked with human whole blood with known hemoglobin concentrations to achieve the following six fecal hemoglobin concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, and 500 ng/mL. Fifty replicates were performed for each concentration level. The results of the repeatability study are described in the table 1 below. Table 1: Repeatability | Lot | Positive Percent Agreement (#Positive/#Total) (95% CI) | Negative Percent Agreement (#Negative/#Total) (95% CI) | | --- | --- | --- | | Lot 1 | 100% (164/164) (97.8%, 100%) | 100% (136/136) (97.3%, 100%) | | Lot 2 | 100% (164/164) (97.8%, 100%) | 97.8% (133/136) (93.7%, 99.5%) | | Lot 3 | 100% (164/164) (97.8%, 100%) | 99.3% (135/136) (96.0%, 99.9%) | | Combined Lots | 100% (492/492) (99.3%, 100%) | 99% (404/408) (97.5%, 99.7%) | Reproducibility was conducted across three POC sites using three device lots (same three lots at all sites), and three untrained users (one at each site) over five days. Hb-free fecal samples were collected and spiked with human whole blood with known hemoglobin concentrations to achieve the following six fecal hemoglobin concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 55 ng/mL, 60 ng/mL, and 500 ng/mL. Fourteen replicates were performed for each sample and concentration level. In addition, Insure FIT FOBT Negative and Positive Controls (K101831) were tested daily to ensure the validity of the candidate test results. The results of the reproducibility study are described in the tables below. {5} Table 2: Reproducibility - Lot Variability | Lot | Positive Percent Agreement (#Positive/#Total) (95% CI) | Negative Percent Agreement (#Negative/#Total) (95% CI) | | --- | --- | --- | | Lot 1 | 100 % (684/684) (99.5%, 100%) | 98.6% (568/576) (97.3%, 99.4%) | | Lot 2 | 100 % (684/684) (99.5%, 100%) | 97% (559/576) (95.3%, 98.3%) | | Lot 3 | 100 % (684/684) (99.5%, 100%) | 96.4% (555/576) (94.5%, 97.7%) | Table 3: Reproducibility - Day Variability | Day | Positive Percent Agreement (#Positive/#Total) (95% CI) | Negative Percent Agreement (#Negative/#Total) (95% CI) | | --- | --- | --- | | Day 1 | 100 % (410/410) (99.1%, 100%) | 95.1% (329/346) (92.3%, 97.1%) | | Day 2 | 100 % (410/410) (99.1%, 100%) | 89% (308/346) (85.2%, 92.1%) | | Day 3 | 100 % (410/410) (99.1%, 100%) | 98.6% (341/346) (96.7%, 99.5%) | | Day 4 | 100 % (410/410) (99.1%, 100%) | 95.4% (330/346) (92.6%, 97.3%) | | Day 5 | 100 % (410/410) (99.1%, 100%) | 96.8% (335/346) (94.4%, 98.4%) | Table 4: Reproducibility - Site Variability | Site | Positive Percent Agreement (#Positive/#Total) (95% CI) | Negative Percent Agreement (#Negative/#Total) (95% CI) | | --- | --- | --- | | Site 1 | 100 % (684/684) (99.5%, 100%) | 97.1% (559/576) (95.3%, 98.3%) | | Site 2 | 100 % (684/684) (99.5%, 100%) | 97.4% (561/576) (95.7%, 98.5%) | | Site 3 | 100 % (684/684) (99.5%, 100%) | 96.7% (557/576) (94.9%, 98%) | b. Linearity/assay reportable range: Prozone/Hook Effect Susceptibility of the Instant-view-plus Immunochemical Fecal Occult Blood Test to {6} prozone effects was evaluated using three test kit lots and two trained laboratory personnel. Hb-free stool specimens spiked with human blood of known hemoglobin concentrations so as to obtain fecal test samples with the following Hb concentrations: 1,000 ng/ml (1 ug/ml), 2,000 ng/ml (2 ug/ml), 3,000 ng/ml (3 ug/ml), 4,000 ng/ml (4 ug/ml), 5,000 ng/mL (5 ug/ml), 50,000 ng/mL (50 ug/ml), and 500,000 ng/mL (500 ug/ml). Twenty aliquots of each sample concentration were mixed with extraction buffer in the specimen collection tubes and tested in a randomized order. It was determined that the Instant-view-plus Immunochemical Fecal Occult Blood Test is not susceptible to prozone/hook effect up to a hemoglobin concentration of 500,000 ng/mL. c. Traceability, Stability, Expected values (controls, calibrators, or methods): **Internal Control** Procedural controls are included in the test device. A burgundy line in the control region (C-line) is the internal procedural control and confirms sufficient specimen volume and correct procedural technique. **External Controls** It is recommended that positive and negative controls be performed to verify proper test performance. External controls are not provided with the test kit. **Stability Studies** Insure FIT FOBT Controls (K101831) were tested daily as part of each stability study to validate expected performance of the test kit. 1. Test Kit Stability (Accelerated) An accelerated stability study was performed by two trained laboratory personnel with three test kit lots, two test kits per lot. Hb-free stool specimens were spiked with human blood (of known hemoglobin concentration) to obtain fecal samples containing six different hemoglobin concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. Each test kit lot was stored at the following temperatures: 20°C (68°F), 23°C (73.4°F), 35°C (95°F), and 60°C (140°F). In this study, it was found that the Instant-view-plus Immunochemical Fecal Occult Blood Test kit is stable for 24 months when stored at the following temperatures, 8–23°C (46.4–73.4°F). 2. Test Kit Stability (Real-Time) A real-time stability study was performed by two trained laboratory personnel with three test kit lots. Hb-free stool specimens were spiked with human blood (of known hemoglobin level) to obtain fecal test samples with the following Hb concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 7 {7} ng/mL. Each test kit lot was stored at room temperature 20–23°C (68–73.4°F) for up to 26 months. The results of the study determined that the Instant-view-plus Immunochemical Fecal Occult Blood Test kit is stable for 24 months at room temperature. d. Detection limit: Not applicable e. Analytical specificity: Insure FIT FOBT Controls (K101831) were tested, tested daily in each study to validate the expected performance of the Instant-view-plus Immunochemical Fecal Occult Blood Test kit. Specificity to human hemoglobin variant The ability of Instant-view-plus Immunochemical Fecal Occult Blood Test to detect human hemoglobin variants was determined by testing stool samples spiked with hemoglobin-A (HbA), hemoglobin-S (HbS) and hemoglobin-C (HbC) at seven different concentrations of each variant. HbA-, HbS-, and HbC-spiked samples were tested at 0 ng/mL, 40 ng/mL, 48 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. For each hemoglobin variant, three aliquots of each of the seven concentrations were mixed with detection buffer in Instant-view-plus Immunochemical Fecal Occult Blood Test collection bottles. Samples were tested in a randomized order. The presence of HbA, HbS, and HbC were detected at concentrations ≥ 48 ng/mL. Cross-Reactivity Cross-reactivity of the Instant-view-plus Immunochemical Fecal Occult Blood Test with animal hemoglobin was evaluated by testing Hb-free stool specimens spiked with known concentrations of human Hb to obtain fecal samples with seven different Hb concentrations: 0 ng/mL, 40 ng/mL, 48 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. Five replicates of each concentration were then spiked with hemoglobin from different animals to include bovine (2000 μg/mL), chicken (500 μg/mL), fish (100 μg/mL), horse (500 μg/mL), goat (500 μg/mL), rabbit (500 μg/mL), pig (500 μg/mL), and sheep (100 μg/mL). All samples were tested in a randomized order. Instant-view-plus™ Immunochemical Fecal Occult Blood Test did not show significant cross-reactivity with any of the animal hemoglobins at the concentration tested. Interfering Substances Susceptibility of Instant-view-plus Immunochemical Fecal Occult Blood Test to interference from peroxidase-rich fruits and vegetables was evaluated. In this study, extracts from vegetables and fruits were evaluated by testing five replicates of Hb-free stool specimens spiked with known concentrations of human Hb solution to obtain fecal samples with seven different Hb concentrations: 0 ng/mL, 40 ng/mL, 48 ng/mL, {8} 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. The five replicates were then spiked with extracts from the following vegetables: broccoli, cantaloupe, cauliflower, horseradish, parsnip, red radish, and turnip. All samples were mixed with detection buffer in Instant-view-plus Immunochemical Fecal Occult Blood Test sample collection bottles and tested in a randomized order. There was no significant interference from the vegetable extracts tested at each Hb concentration. ## Interfering Supplements Susceptibility of Instant-view-plus Immunochemical Fecal Occult Blood Test to interference from iron and sodium L-ascorbate was evaluated by testing Hb-free stool specimen spiked with known concentrations of human Hb solution to obtain fecal samples with seven different Hb concentrations: 0 ng/mL, 40 ng/mL, 48 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. Three aliquot samples for each Hb concentration, were spiked with iron (0.5% (w/v)) or sodium L-ascorbate (0.5% (w/v)). All samples were mixed with detection buffer in Instant-view-plus Immunochemical Fecal Occult Blood Test sample collection bottles and tested in a randomized order. Instant-view-plus Immunochemical Fecal Occult Blood Test did not show significant interference from iron (0.5% (w/v)) or sodium L-ascorbate (0.5% (w/v)). ## Interference from Toilet Water Susceptibility of Instant-view-plus Immunochemical Fecal Occult Blood Test to interference from toilet water was evaluated by testing 40 replicates of Hb-free stool specimen spiked with known concentrations of human Hb solution to obtain fecal samples with seven different fecal Hb concentrations: 0 ng/mL, 40 ng/mL, 48 ng/mL, 50 ng/mL, 60 ng/mL, 72 ng/mL, and 500 ng/mL. Twenty replicates of each spiked sample were collected both without contact with toilet water and after being submerged in toilet water. All samples were mixed with detection buffer in Instant-view-plus Immunochemical Fecal Occult Blood Test sample collection bottles and tested in a randomized order. Instant-view-plus Immunochemical Fecal Occult Blood Test did not show significant interference from samples collected in toilet water. ## f. Assay cut-off: The cut-off value for the Instant-view-plus Immunochemical Fecal Occult Blood (FOB) Test was verified against the predicate cutoff. Fecal test samples were prepared by spiking stool samples with human blood of known hemoglobin concentration, to obtain the following fecal hemoglobin concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 48 ng/mL, 60 ng/mL, 72 ng/mL and 500 ng/mL. Twenty aliquots of each of the seven concentrations of spiked stool test samples were tested in randomized order. Testing was performed side-by-side with the predicate by comparing the test results of the device with that of the predicate. The cut-off was verified to 50 ng/mL (hemoglobin in fecal sample mixed with detection buffer). 9 {9} | Concentration (ng/mL) | N | Instant-view plus Immunochemical Fecal Occult Blood Test | | Positive Percent Agreement (95% CI) | Negative Percent Agreement (95% CI) | | --- | --- | --- | --- | --- | --- | | | | Positive | Negative | | | | 0 | 20 | 0 | 20 | 0% (0%, 16.8%) | 100.00% (83.2%, 100%) | | 25 | 20 | 1 | 19 | 5% (0.1%, 24.9%) | 95% (75.1%, 99.9%) | | 48 | 20 | 11 | 9 | 55% (39.1%, 70.8%) | 45% (29.2%, 60.8%) | | 50 | 20 | 11 | 9 | 55% (31.5%, 76.9%) | 45% (23.1%, 68.5%) | | 60 | 20 | 20 | 0 | 100% (83.2%, 100%) | 0% (0%, 16.8%) | | 72 | 20 | 20 | 0 | 100% (83.2%, 100%) | 0% (0%, 16.8%) | | 500 | 20 | 20 | 0 | 100% (83.2%, 100%) | 0% (0%, 16.8%) | 2. Comparison studies: a. Method comparison with predicate device: A method comparison of Instant-view-plus Immunochemical Fecal Occult Blood (FOB) Test with the predicate test, Instant-View Fecal Occult Blood Rapid Test, was conducted by testing 299 patient samples. The method comparison study was performed at three POC sites with two untrained users at each site. The Insure FIT FOBT Controls (K101831) were run prior to testing study samples. Statistical analysis of site-wise test results as well as combined results showed that Instant-view-plus Immunochemical Fecal Occult Blood (FOB) Test results have acceptable overall percent agreement as well as positive percent agreement and negative percent agreement with the Instant-View Fecal Occult Blood Rapid Test. | Study Site | Instant-view-plus Immunochemical FOB Test | Predicate Test | | | Negative Percent Agreement (95% CI) | Positive Percent Agreement (95% CI) | Overall Percent Agreement (95% CI) | | --- | --- | --- | --- | --- | --- | --- | --- | | | | Instant-View Fecal Occult Blood Rapid Test | | | | | | | | | Positive | Negative | Total | | | | | Site 1 | Positive | 36 | 1 | 37 | 98.5% (92.1%, 99.9%) | 94.7% (82.3%, 99.4%) | 97.2% (92.0%, 99.4%) | | | Negative | 2 | 67 | 69 | | | | | | Total | 38 | 68 | 106 | | | | | Site 2 | Positive | 36 | 1 | 37 | 98.9% (93.8%, 99.9%) | 97.3% (85.8%, 99.9%) | 98.4% (94.3%, 99.8%) | | | Negative | 1 | 87 | 88 | | | | | | Total | 37 | 88 | 125 | | | | | Site 3 | Positive | 25 | 1 | 26 | 97.6% (87.4%, 99.9%) | 96.2% (80.4%, 99.9%) | 97.1% (89.8%, 99.6%) | | | Negative | 1 | 41 | 42 | | | | | | Total | 26 | 42 | 68 | | | | | Combined Sites | Positive | 97 | 3 | 100 | 98.5% (95.6%, 99.7%) | 6.0% (90.2%, 98.9%) | 97.7% (95.2%, 99.1%) | | | Negative | 4 | 195 | 199 | | | | | | Total | 101 | 198 | 299 | | | | {10} In addition, a consumer study with over-the-counter untrained users was performed by testing the Instant-view-plus Immunochemical Fecal Occult Blood (FOB) Test in parallel to the predicate test, the INSTANT-VIEW Fecal Occult Blood (FOB) Self-Test. In this study, Hb-free stool specimens were spiked with hemoglobin to obtain fecal samples with the following hemoglobin concentrations: 0 ng/mL, 25 ng/mL, 50 ng/mL, 60 ng/mL, and 500 ng/mL. The results of this study are shown in the table below. | Concentration (ng/mL) | Number of Samples | Predicate Device | | New Device | | Difference (New - Predicate) | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | Negative (%) | Positive (%) | Negative (%) | Positive (%) | Negative % (95% CI of Difference) | Positive % (95% CI of Difference) | | 0 | 54 | 54 | 0 | 54 | 0 | 0 (-6.8%, 6.8%) | 0 (-6.8%, 6.8%) | | 25 | 54 | 52 | 2 | 53 | 1 | 1.9% (-6.8%, 1.1%) | -1.9% (-11.1%, 6.8%) | | 50 | 54 | 25 | 29 | 26 | 28 | 1.9% (-17.4%, 21.0%) | -1.9% (-21.0%, 17.4%) | | 60 | 54 | 1 | 53 | 1 | 53 | 0 (-8.6%, 8.6%) | 0 (-8.6%, 8.6%) | | 500 | 54 | 0 | 54 | 0 | 54 | 0 (-6.8%, 6.8%) | 0 (-6.8%, 6.8%) | b. Matrix comparison: Not applicable 3. Clinical studies: a. Clinical Sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a. and b. are not applicable): 1. Specimen Collection Verification: The purpose of this study was to verify that the applicator device for the Instant-view-plus Immunochemical Fecal Occult Blood Test kit, consistently delivers the specified amount of stool required for optimal test performance. The study was conducted by five untrained users who each tested five positive and five negative clinical samples. The amount of stool specimen collected using the applicator {11} device, did not show a significant difference between users. The average weight of the stool specimens collected by the users was 0.94 mg. Results found that by following the instructions for use in the labeling, an accurate amount of sample can be obtained. 2. Sample Volume Study: The sample test volume compatible with accurate and consistent performance of the Instant-view-plus Immunochemical Fecal Occult Blood Test was demonstrated in a study that evaluated three device lots tested with both a negative sample (25 ng/ml) and a positive sample (60 ng/ml). One to five drops of each sample were tested for each device lot.. In order for the sample volume to be considered adequate for test performance, the control (C) line had to appear in less than 20 seconds and the test (T) line had to appear within one min for positive samples (and be absent for negative samples). The sample volume study demonstrated that for Instant-view-plus Immunochemical Fecal Occult Blood Test device, one drop of sample consistently produced correct results within the specified timeframe. 4. Clinical cut-off: Not applicable 5. Expected values/Reference range: Not applicable N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable. O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. 12
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...